J. Robert Flamini

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

David Neal Franz, Steven Sparagana, E. Martina Bebin et al. · The Lancet · 2012 · 771 citations

Tuberous Sclerosis Complex, Neuro-oncology, Placebo-controlled Phase 3 +7

Adjunctive perampanel for refractory partial-onset seizures

Jacqueline A. French, Gregory L. Krauss, Victor Biton et al. · Neurology · 2012 · 470 citations · Full text

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

David Neal Franz, Steven Sparagana, E. Martina Bebin et al. · PLoS ONE · 2016 · 203 citations · Full text

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study

David Neal Franz, Steven Sparagana, E. Martina Bebin et al. · The Lancet Oncology · 2014 · 176 citations

Tuberous Sclerosis Complex, Neuro-oncology, Glioma +9

The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1

J.C. Kingswood, Sergiusz Jóźwiak, Michael Frost et al. · Nephrology Dialysis Transplantation · 2014 · 79 citations · Full text